Reactions 1404 - 2 Jun 2012

SAntineoplastics

Premature ovarian failure: case reportA woman [age at onset not clearly stated] developed

premature ovarian failure following administration ofcyclophosphamide, dactinomycin, doxorubicin, etoposide,ifosfamide and vincristine [dosages, routes and durations oftreatments not stated].

The woman was diagnosed with rhabdomyosarcoma at25 years of age, and received chemotherapy withcyclophosphamide, doxorubicin and vincristine. After1 year, she had disease recurrence, and receivedchemotherapy with dactinomycin, etoposide andifosfamide alternating with cyclophosphamide,dactinomycin and vincristine. Three years later, shepresented with amenorrhoea. Tests revealed a serumfollicle stimulating hormone (FSH) level of 80 IU/L, a serumluteinising hormone level of 100 IU/L, and low levels ofserum estradiol and progesterone. She was diagnosed withchemotherapy-induced premature ovarian failure.

The woman received hormone replacement therapy withestradiol valerate/norgestrel for menopausal symptoms.The following year, she had a spontaneous viableintrauterine pregnancy. She subsequently delivered viacaesarean section. Six months later, tests revealed a serumFSH level of 100 IU/L, and she restarted estradiol valerate/norgestrel. Five months after delivery, her tumour recurred,and she received vincristine and irinotecan. Two yearslater, she presented with amenorrhoea of 5 months’duration, and was diagnosed with pregnancy at 20 weeksgestation; however, she developed new recurrence ofrhabdomyosarcoma. She delivered a health baby at35 weeks gestation, and chemotherapy was restarted. At7 years’ follow-up, she was doing well.Ghazeeri G, et al. Two successful pregnancies in a patient with chemotherapy-induced ovarian failure while on hormone replacement therapy. GynecologicalEndocrinology 28: 286-287, No. 4, Apr 2012. Available from: URL: http://dx.doi.org/10.3109/09513590.2011.633657 - Lebanon 803071248

1

Reactions 2 Jun 2012 No. 14040114-9954/10/1404-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved